-move to increase efficiency and better position Company for strategic
BELLEVILLE, ON, Jan. 3 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company,
today announced a reorganization of its corporate leadership team with
a goal of increasing efficiency and better positioning the Company for
strategic growth. This reorganization takes effect immediately.
Bioniche Animal Health Leadership
In the Bioniche Animal Health business unit, Jim Phillips, President of
Bioniche Animal Health (global) has taken on a new role as Senior
Vice-President, Industry Relations. This is a strategic position that
will enable the Company to be more proactive in its pursuit of
potential product and technology acquisitions, as well as to be more
engaged with the veterinarian community as a whole, the customers of
Bioniche Animal Health. Jim has been with Bioniche for 25 years, and is
well-known in the animal health industry in North America and beyond.
He has provided strong leadership to the Animal Health division and
will continue to grow the Company's animal health business in this new
Andrew Grant, Divisional President of Bioniche Animal Health Export
Sales, Europe and A/Asia, has been promoted to President of Bioniche
Animal Health (global). Andrew has been with the Company for 12 years,
starting as Managing Director of Bioniche Animal Health A/Asia. He has
a broad depth of knowledge of the industry and an excellent awareness
of potential future growth opportunities for the business.
Bioniche Human Health Clinical Leadership
In the Company's Human Health business unit, Dr. François Charette,
Senior Vice-President of Medical Affairs and Chief Medical Officer, has
left Bioniche to pursue new career opportunities. The Medical Affairs
group is now under the leadership of Monique Champagne, Vice-President,
Clinical Research. In this role, Monique will be working with the Human
Health team to identify and pursue new human health indications for the
Company's core proprietary Mycobacterial Cell Wall-DNA Complex (MCC)
technology. Monique joined the Company as Director, Clinical Research
"Having successfully concluded an equity financing in December, the
Company is poised with the financial resources it requires to more
efficiently advance a number of its key strategic projects," said
Graeme McRae, Chairman, President & CEO of Bioniche Life Sciences Inc.
"At the same time, we must ensure that we have the appropriate people
in key leadership positions to take advantage of the opportunities in
front of us. I believe that the administrative reorganization achieves
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary products for
human and animal health markets worldwide. The fully-integrated company
employs 217 skilled personnel and has three operating divisions: Human
Health, Animal Health, and Food Safety. The Company's primary goal is
to develop proprietary cancer therapies supported by revenues from
marketed products in human and animal health. For more information,
please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058
Cell: (613) 391-2097